Africa is about to make its own vaccines at scale — and the first cheques are landing this year
Gavi will make the first cash disbursements from its $1.2 billion African Vaccine Manufacturing Accelerator to an African manufacturer in the second half of 2026 — the moment a decade-long push to end the continent's dependence on imported vaccines turns from blueprint into balance sheet.
When COVID-19 swept the world in 2021, Africa learned a brutal lesson in dependency: home to about 18% of humanity, it manufactured less than 1% of the vaccines its people needed, and watched wealthier nations empty the global supply first. Five years on, the machinery built to make sure that never happens again is about to move real money — and that is genuinely good news.
What happened
Gavi, the Vaccine Alliance, will make the first cash disbursements from its African Vaccine Manufacturing Accelerator (AVMA) to an African manufacturer in the second half of 2026, Semafor reported this week. The payments are small in the scheme of a $1.2 billion, ten-year programme, but they matter symbolically and practically: they mark the point where AVMA crosses from construction into commercialisation — from building factories to paying for doses that come out of them.
AVMA, launched by Gavi in June 2024, is a financing instrument that makes up to $1.2 billion available over a decade to support the sustainable growth of Africa's vaccine-manufacturing base. Rather than simply funding buildings, it works through demand-linked incentives — payments tied to manufacturers actually producing and supplying qualified vaccines — which is the harder, more durable problem to solve.
Why it matters
The progress underneath the headline is substantial. In its first roughly 18 months, AVMA has helped secure thirteen individual technology-transfer agreements between African manufacturers and global partners, leading to commercial-scale manufacturing facilities being built across six African countries, according to Gavi. Since the accelerator launched in 2024, some $3 billion in additional financing has been mobilised around it — a signal that private and institutional capital is following the anchor commitment rather than waiting on the sidelines.
The destination is explicit: the African Union and Africa CDC want the continent to produce 60% of the vaccines it uses by 2040, up from that sub-1% pandemic-era floor. Local manufacturing is not merely about pride or price. It is about proximity — vaccines made on the continent can reach outbreaks faster, are less exposed to export bans in the next global emergency, and build the scientific and industrial base that a young, growing population will need for decades.
The exponential-growth lens
Himilo Post's read: vaccine manufacturing is an ecosystem, not a factory, and ecosystems compound. Gavi is already proposing a further $189 million package — an initiative reported as AVMA+ — aimed at the two things a factory alone cannot fix: strengthening Africa's medicines regulators so their approvals are trusted globally, and guaranteeing demand by committing to purchase up to 70 million doses of African-made vaccines through competitive tenders once they reach market. "Some of the funding will go to ensure that the ecosystem is fully operational, especially regulatory," Afrigen Biologics chief executive Petro Terblanche told Devex, "because without that, the manufacturers cannot be sustainable." Each piece makes the next viable: capable regulators unlock guaranteed demand, guaranteed demand justifies the factories, and working factories give the regulators something real to approve. With thirteen tech-transfer deals in place, the first Africa-made, AVMA-supported vaccines could be deployed as early as 2027.
What's next
The milestones to watch are concrete: the first AVMA disbursement before year-end, the Gavi board's decision on the $189 million AVMA+ proposal, and the first products rolling off the six countries' new lines toward a 2027 deployment. Africa's vaccine-sovereignty goal still faces real headwinds — tightening global health budgets chief among them. But the direction is set, the factories are rising, and for the first time the money is moving in the right direction. A continent that was last in line in 2021 is building the capacity to be first responder to its own health in the decade ahead.
